Bristol Myers, Exelixis Reveal 4-Year Follow-Up Results From Cancer Treatment Study
Portfolio Pulse from Vandana Singh
Bristol Myers Squibb (BMY) and Exelixis Inc (EXEL) announced four-year follow-up results from the CheckMate -9ER trial, showing their combination treatment of Opdivo and Cabometyx outperformed Pfizer's (PFE) Sutent in treating advanced renal cell carcinoma. The combination treatment nearly doubled median progression-free survival and overall survival compared to Sutent, with significant improvements in response rates and duration of response across different risk groups. These results will be presented at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium.
January 23, 2024 | 4:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bristol Myers Squibb's positive trial results for Opdivo in combination with Cabometyx could bolster investor confidence and potentially lead to increased sales, positively impacting BMY's stock in the short term.
The positive trial results are directly related to Bristol Myers Squibb's product and can lead to increased usage and sales, which is likely to be viewed favorably by investors.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Exelixis Inc's collaboration with Bristol Myers Squibb on the successful cancer treatment could positively influence EXEL's stock price as the company may benefit from the treatment's potential market success.
Exelixis is directly involved in the successful trial, which could lead to increased market share and revenue from the treatment, positively affecting the company's financials and stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 90
NEGATIVE IMPACT
Pfizer's Sutent was outperformed by the combination treatment of Opdivo and Cabometyx in the CheckMate -9ER trial, which could negatively impact PFE's stock in the short term due to potential market share loss.
The trial results suggest that Pfizer's product is less effective than the competing treatment, which could lead to a decrease in Sutent's market share and sales, potentially harming Pfizer's stock price.
CONFIDENCE 75
IMPORTANCE 60
RELEVANCE 70